|
|
Abstract:
Peri-Anal Crohn’s Disease
(Click here for the entire article)
Efficacy of Topical Metronidazole (10 Percent) in the
Treatment of Anorectal Crohn’s Disease
Edward E. Stringer, MD, Thomas J. Nicholson, MD, David
Armstrong, MD
Purpose:
The aim of this study was to investigate the efficacy of 10
percent topical metronidazole in the treatment of symptomatic
anorectal Crohn’s disease.
METHODS: Patients with symptomatic anorectal Crohn’s
disease were studied in a prospective, nonblinded, nonrandomized
study to evaluate the efficacy of topical 10 percent
metronidazole. Perianal Crohn’s Disease Activity Index and each
component (pain, discharge, induration, sexual dysfunction, and
type of pathology) were recorded before treatment and at four
weeks. Visual analog pain score (0-10) was recorded before
treatment and at weekly intervals for up to four weeks.
RESULTS: Fourteen patients were studied prospectively for
four weeks. Mean Perianal Crohn’s Disease Activity Index
decreased from 8.8 + 0.9 before treatment to 4.1 + 0.7 after
four weeks’ treatment (P<0.0001). Visual analog pain scores
decreased from 5.4 + 0.7 before treatment to 2.4 + 0.5 at one
week (P<0.001) and to 1.0 + 0.4 after four weeks’ treatment)
(P<0.0001). Of the Perianal Crohn’s Disease Activity Index
components, significant decreases were noted in pain and
discharge (P<0.0001) and induration (P<0.001).
CONCLUSION: For patients with Perianal Crohn’s disease,
topical 10 percent metronidazole decreases the Perianal Crohn’s
Disease Activity Index and anorectal pain.
back to top
|
